Business Context and Reporting Period
Kestra Medical Technologies, Ltd. (KMTS) filed a Form 8-K on July 10, 2026, reporting the entry into a new material definitive loan agreement and the termination of a prior loan agreement. The filing also references financial results for the fiscal quarter ended April 30, 2026, announced via press release on July 14, 2026.
Key Financial Metrics and Capital Structure
- New Debt Facility: A five-year senior secured term loan facility of up to $200.0 million.
- Tranche A (Funded): $75.0 million committed loan funded on July 10, 2026.
- Tranche B (Committed): $25.0 million available at the Borrower's option through July 31, 2027.
- Tranche C (Committed): $50.0 million available upon reaching $150.0 million in trailing twelve-month revenue, requestable by June 30, 2028.
- Tranche D (Uncommitted): $50.0 million available for acquisitions subject to lender approval.
- Net Proceeds: Approximately $20.0 million from Tranche A after costs and repayment of prior debt.
- Interest Rate: Variable rate of 5.50% plus three-month SOFR (with a 3.25% SOFR floor).
- Amortization: 48 months of interest-only payments; principal amortization begins in Q2 2030.
- Liquidity Covenant: Minimum liquidity of $20.0 million in cash and cash equivalents required at all times.
Material Changes Versus Prior Period
The Company terminated its Prior Loan Agreement with Perceptive Credit Holdings IV, LP, which was entered into on September 29, 2023. All obligations under the prior agreement were paid in full and discharged on July 10, 2026, and the prior lender's security interests were released. The new facility replaces the prior debt structure with a larger, tranche-based facility extending to 2031.
Guidance, Outlook, and Risks
Management Commentary and Use of Proceeds: Remaining proceeds from the Tranche A funding will be used for general corporate and working capital requirements. The Company has secured access to additional capital contingent on revenue milestones (Tranche C) and acquisition opportunities (Tranche D).
Risks and Covenants: The Loan Agreement includes restrictive covenants limiting additional indebtedness, liens, dividends, and mergers. The debt is secured by substantially all assets, including intellectual property. Prepayment is subject to make-whole provisions and exit fees. The filing does not provide specific revenue or profit figures for the quarter ended April 30, 2026, as those details are contained in the referenced press release (Exhibit 99.1) and are not deemed "filed" for Section 18 purposes.
Investor Verification Checklist
- Verify the specific revenue and profit figures for the quarter ended April 30, 2026, in the July 14, 2026 press release (Exhibit 99.1).
- Confirm the Company's current cash balance to ensure compliance with the $20.0 million minimum liquidity covenant.
- Assess the feasibility of reaching the $150.0 million trailing twelve-month revenue threshold required to access the $50.0 million Tranche C funding.
- Review the full text of the Loan Agreement (to be filed in the 10-K) for detailed prepayment penalties and change of control provisions.